Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| No statute on record | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TOWNSLEY, SARA ELIZABETH | 1 | 25.3% | +48.6% |
| ELENISTE, PIERRE PAUL | 1 | 38.5% | +30.2% |
| WU, JULIE ZHEN QIN | 1 | 61.8% | +52.2% |
| PECKHAM, RICHARD GRANT | 1 | 68.3% | +35.6% |
| BUTTICE, AUDREY L | 1 | 45.8% | +21.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18351439 | COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS | TOWNSLEY, SARA ELIZABETH | 22d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16894532 | TRIPLET THERAPIES OF HDAC INHIBITORS, PD-L1 AND/OR PD-1 INHIBITORS, AND CTLA-4 INHIBITORS | BUTTICE, AUDREY L | 35d overdue |
| 18351439 | COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS | TOWNSLEY, SARA ELIZABETH | 22d overdue |
| 17410459 | METHODS AND COMPOSITIONS FOR GENETIC MODULATION OF TUMOR MICROENVIRONMENTS | PECKHAM, RICHARD GRANT | 15d overdue |
| 18120311 | MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF | ELENISTE, PIERRE PAUL | 8d |
| 17993567 | COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS | WU, JULIE ZHEN QIN | 12d |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1622 | 1 |
| 1643 | 1 |
| 1627 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18351439 | COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS | TOWNSLEY, SARA ELIZABETH | 1629 | Other | Non-Final OA | 22d overdue | Pending | Jul 12, 2023 |
| 18120311 | MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF | ELENISTE, PIERRE PAUL | 1622 | Other | Non-Final OA | 8d | Pending | Mar 10, 2023 |
| 17993567 | COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS | WU, JULIE ZHEN QIN | 1643 | Other | Final Rejection | 12d | Pending | Nov 23, 2022 |
| 17410459 | METHODS AND COMPOSITIONS FOR GENETIC MODULATION OF TUMOR MICROENVIRONMENTS | PECKHAM, RICHARD GRANT | 1627 | §103 | Final Rejection | 15d overdue | Pending | Aug 24, 2021 |
| 16894532 | TRIPLET THERAPIES OF HDAC INHIBITORS, PD-L1 AND/OR PD-1 INHIBITORS, AND CTLA-4 INHIBITORS | BUTTICE, AUDREY L | 1647 | §103 | Non-Final OA | 35d overdue | Pending | Jun 05, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial